US74834L1008
© PR Newswire
19.12.2025
DGX
LISTED
NYSE
Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SECAUCUS, N.J., Dec. 19, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading national provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest marke...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2025
DGX
LISTED
NYSE
Quest Diagnostics Declares Quarterly Cash Dividend
News Preview
SECAUCUS, N.J., Nov. 11, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record of Quest Diagnostics common stock on Ja...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
DGX
LISTED
NYSE
Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference
News Preview
SECAUCUS, N.J., Nov. 3, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends duri...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
27.10.2025
DGX
LISTED
NYSE
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
News Preview
The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation
SECAUCUS, N.J., Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
24.10.2025
DGX
LISTED
NYSE
MVZ HPH führt ctDNA-Bluttest zur Krebsüberwachung in Europa ein, basierend auf der Haystack MRD®-Technologie von Quest Diagnostics®
News Preview
Bluttest zur Unterstützung der Krebsbehandlung und Überwachung von Rückfällen ist nun in einem deutschen Labor verfügbar und ermöglicht potenziell schnellere Ergebnisse
HAMBURG, Deutschland, 24. Oktober 2025 /PRNewswire/ -...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
DGX
LISTED
NYSE
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
News Preview
Third quarter revenues of $2.82 billion, up 13.1% from 2024
Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024
Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
DGX
LISTED
NYSE
MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®
News Preview
Blood test to aid cancer treatment and recurrence monitoring now available from a German lab for potentially faster results
HAMBURG, Germany, Oct. 17, 2025 /PRNewswire/ -- MVZ HPH Institute for Pathology and Hematopatholo...
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2025
DGX
LISTED
NYSE
Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025
News Preview
SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2025
DGX
LISTED
NYSE
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration
News Preview
With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and their patients
SECAUCUS, N.J., Sept. 23, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Epic today announced a first-of-its-kind collaboration...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
DGX
LISTED
NYSE
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
News Preview
SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize p...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
DGX
LISTED
NYSE
WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App
News Preview
WHOOP, the human performance company, today announced that Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will be the U.S. lab provider for WHOOP Advanced Labs, a new WHOOP feature that provides laboratory insights supporting health and performance. The offering will provide the option to purchase Quest’s cli...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
DGX
LISTED
NYSE
Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference
News Preview
SECAUCUS, N.J., Sept. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Jefferies Healthcar...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
04.09.2025
DGX
LISTED
NYSE
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
News Preview
New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties
SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test service designed to h...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
DGX
LISTED
NYSE
Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
News Preview
Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020
SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in pre-employment testing, according to the 2025 Quest Diagnost...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2025
DGX
LISTED
NYSE
Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan
News Preview
Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state
Quest will also manage Corewell Health's 21 hospital labs
SOUTHFIELD, Mich. and GRAND RAPIDS, Mich. and SECAUCUS, N.J., Aug. 26, 2025 /PRNewswire/ -- Corewell Health and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic info...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
DGX
LISTED
NYSE
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
News Preview
SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer...
Themefolio
Profiler
Peergroup
© PR Newswire
16.08.2025
DGX
LISTED
NYSE
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
News Preview
SECAUCUS, N.J., Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2025 Global Healthcare Conference in New York...
Themefolio
Profiler
Peergroup
© PR Newswire
14.08.2025
DGX
LISTED
NYSE
Quest Diagnostics Declares Quarterly Cash Dividend
News Preview
SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
07.08.2025
DGX
LISTED
NYSE
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
News Preview
SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research...
Themefolio
Profiler
Peergroup
© PR Newswire
05.08.2025
DGX
LISTED
NYSE
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care
News Preview
SECAUCUS, N.J., Aug. 5, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of select clinical testing assets of Fresenius Medical Care's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory t...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
DGX
LISTED
NYSE
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
News Preview
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease
BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
DGX
LISTED
NYSE
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
News Preview
Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024Year-to-date cash provided by operations of $858 million, up 67.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.60 a...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
DGX
LISTED
NYSE
Quest Diagnostics Introduces Testing for Oropouche Virus
News Preview
Diagnostic testing for emerging infectious disease associated with severe neurological affects
SECAUCUS, N.J., July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging disease that is increasingly fo...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2025
DGX
LISTED
NYSE
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
News Preview
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients
SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health,...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
DGX
LISTED
NYSE
Quest Diagnostics Releases 2024 Corporate Responsibility Report
News Preview
SECAUCUS, N.J., June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report.
The theme of the report, Care Starts Here, reflects...
Themefolio
Profiler
Peergroup
© PR Newswire
23.06.2025
DGX
LISTED
NYSE
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025
News Preview
SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. East...
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2025
DGX
LISTED
NYSE
Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology
News Preview
SECAUCUS, N.J., June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appro...
Themefolio
Profiler
Peergroup
© PR Newswire
20.05.2025
DGX
LISTED
NYSE
More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals
News Preview
Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025
Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss preventive care and wellness with them; More than half of millennials, Gen Z cite barriers to accessing medical care
SECAUCUS, N.J., May 20, 2025 /...
Themefolio
Profiler
Peergroup
© PR Newswire
16.05.2025
DGX
LISTED
NYSE
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
News Preview
SECAUCUS, N.J., May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth S...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
DGX
LISTED
NYSE
Quest Diagnostics Declares Quarterly Cash Dividend
News Preview
SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
DGX
LISTED
NYSE
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds
News Preview
More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors that we don't understand yet"Missed/delayed follow-up care or monitoring appointments by patients (68%) and imaging tests not detecting recurrence ear...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
DGX
LISTED
NYSE
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025
News Preview
First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.8...
Themefolio
Profiler
Peergroup
© PR Newswire
09.04.2025
DGX
LISTED
NYSE
Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease
News Preview
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity
SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanc...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
DGX
LISTED
NYSE
Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
News Preview
Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection
Quest also plans to make self-collection option available at its 2,000 patient service centers in the Unit...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
DGX
LISTED
NYSE
Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025
News Preview
SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. East...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
DGX
LISTED
NYSE
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day
News Preview
Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGRReaffirms guidance for full year 2025SECAUCUS, N.J., March 19, 2025 /PRNewswire/ -- At a meeting with analysts and investors at its 2025 Investor Day, members of the l...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
DGX
LISTED
NYSE
Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI
News Preview
SUNNYVALE, Calif. and SECAUCUS, N.J., March 18, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and personalize the experiences Quest delivers to patients, providers and other customers....
Themefolio
Profiler
Peergroup
© PR Newswire
13.02.2025
DGX
LISTED
NYSE
Quest Diagnostics to Host Investor Day on March 19, 2025
News Preview
SECAUCUS, N.J., Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange. ...
Themefolio
Profiler
Peergroup
© PR Newswire
30.01.2025
DGX
LISTED
NYSE
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 11th Consecutive Year
News Preview
SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companie...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
DGX
LISTED
NYSE
Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer
News Preview
Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team
SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L. Brott, an accomplished quality and regulatory affairs healthcare leader, has been...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
DGX
LISTED
NYSE
Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025
News Preview
SECAUCUS, N.J., Jan. 2, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
DGX
LISTED
NYSE
Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference
News Preview
SECAUCUS, N.J., Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Co...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
DGX
LISTED
NYSE
Quest Diagnostics Launches Health Coaching on questhealth.com to Help Individuals Take Control of Their Health
News Preview
New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching
SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ -- Personalized, one-on-one health coaching is now available for purchase on questhealth.com. Made available by Pack Health®, a Quest Diagnostics (NYSE: DGX) c...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
DGX
LISTED
NYSE
Quest Diagnostics Declares Quarterly Cash Dividend
News Preview
SECAUCUS, N.J., Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2024
DGX
LISTED
NYSE
Quest Diagnostics Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development
News Preview
Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month based on one of the awards
SECAUCUS, N.J., Oct. 23, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information se...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2024
DGX
LISTED
NYSE
Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
News Preview
Third quarter revenues of $2.49 billion, up 8.5% from 2023Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023Full year 2024 revenues now expected to be between $9.80 billion and $9.85 billion; reported diluted EPS now expected to be between $7.60 and $7.70; an...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
DGX
LISTED
NYSE
Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers
News Preview
First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium
Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or t...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2024
DGX
LISTED
NYSE
Quest Diagnostics Completes Acquisition of Lab Assets from OhioHealth
News Preview
Goal to broaden access to cost-effective and innovative laboratory services in Ohio
SECAUCUS, N.J., Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from OhioHealth, a nationally recogniz...
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2024
DGX
LISTED
NYSE
Quest Diagnostics to Release Third Quarter 2024 Financial Results on October 22, 2024
News Preview
SECAUCUS, N.J., Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. E...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2024
DGX
LISTED
NYSE
Sentara Health Plans and Quest Diagnostics Form Strategic Collaboration to Extend Lab Access in Parts of the Southeast
News Preview
Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida
SECAUCUS, N.J and HAMPTON ROADS, Va., Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Sentara Health Plans, the health plan division of Sentara Health, an integrated...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
DGX
LISTED
NYSE
Quest Diagnostics Completes Acquisition of Select Lab Assets from Allina Health
News Preview
SECAUCUS, N.J., Sept. 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from Allina Health....
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
DGX
LISTED
NYSE
Quest Diagnostics to Speak at the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
SECAUCUS, N.J., Aug. 28, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Morgan Stanley 22nd Annual Globa...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
DGX
LISTED
NYSE
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
News Preview
SECAUCUS, N.J. and TORONTO, Aug. 26, 2024 /CNW/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at approximately CAN $1.35 billion (approximately USD $1 billion), including net debt, has received all necessary...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
DGX
LISTED
NYSE
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
News Preview
SECAUCUS, N.J. and TORONTO, Aug. 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at approximately CAN $1.35 billion (approximately USD $1 billion), including net debt, has received all ne...
Themefolio
Profiler
Peergroup
© PR Newswire
21.08.2024
DGX
LISTED
NYSE
Quest Diagnostics to Acquire University Hospitals' Outreach Laboratory Services Business
News Preview
Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio
SECAUCUS, N.J., and CLEVELAND, Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and University Hospitals, one of the nation's leading nonprofit health systems and...
Themefolio
Profiler
Peergroup
© PR Newswire
16.08.2024
DGX
LISTED
NYSE
Quest Diagnostics Prices $1.85 Billion of Senior Notes
News Preview
SECAUCUS, N.J., Aug. 15, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the "2027 notes"), $600 million aggregate principal amount of its 4....
Themefolio
Profiler
Peergroup
© PR Newswire
15.08.2024
DGX
LISTED
NYSE
questhealth.com Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies
News Preview
Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions
SECAUCUS, N.J., Aug. 15, 2024 /PRNewswire/ -- Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but...
Themefolio
Profiler
Peergroup
© PR Newswire
15.08.2024
DGX
LISTED
NYSE
Quest Diagnostics Declares Quarterly Cash Dividend
News Preview
SECAUCUS, N.J., Aug. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October 21, 2024 to shareholders of record of Quest Diagnostics common stock on October 4, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2024
DGX
LISTED
NYSE
Pregnant Women Undertested for STIs, Finds Quest Diagnostics Health Trends® Study of Over 4 Million Pregnancies
News Preview
One in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns
SECAUCUS, N.J., Aug. 12, 2024 /PRNewswire/ -- A new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of Alabama suggests adherence to guideline-based...
Themefolio
Profiler
Peergroup
© PR Newswire
23.07.2024
DGX
LISTED
NYSE
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
News Preview
Second quarter revenues of $2.40 billion, up 2.5% from 2023Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2% from 2023Full year 2024 revenues now expected to be between $9.50 billion and $9.58 billion; reported diluted EPS now expected to be between $7.57 and $7.77...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
